GlassScriptPhysician profile
Cynthia Carrillo
NPI 1245675537
$6,912.61
in general payments reported to CMS, 2019-2025
36 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2022: $267 · 2023: $2,193 · 2024: $1,857 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,446.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,053.51 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $963.46 | 2022-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $445.83 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.94 | 2025 | Caplyta |
| Exact Sciences Corporation | $263.16 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $258.84 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $245.50 | 2022-2025 | |
| Abbvie INC. | $232.22 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Nevro Corp. | $196.16 | 2023-2024 | Senza |
| Genentech USA, INC. | $186.78 | 2019 | |
| Novo Nordisk INC | $129.89 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $127.18 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.89 | 2024-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $100.40 | 2023-2025 | Ajovy, Austedo Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $97.80 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.10 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $55.69 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $50.88 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $47.34 | 2023 | Quviviq |
| Eisai INC. | $45.96 | 2025 | |
| Nestle Healthcare Nutrition INC. | $45.76 | 2023 | |
| Gilead Sciences, INC. | $40.28 | 2023-2025 | Epclusa |
| Sumitomo Pharma America, INC. | $39.50 | 2025 | Gemtesa |
| Astellas Pharma US INC | $35.44 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $33.95 | 2022 | |
| Corcept Therapeutics | $29.91 | 2024 | Korlym |
| Boston Scientific Corporation | $23.70 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $23.05 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.91 | 2025 | Gvoke Hypopen |
| Ascensia Diabetes Care US INC. | $19.53 | 2023 | |
| Medtronic, INC. | $18.99 | 2022 | |
| Sanofi Pasteur INC. | $16.44 | 2023 | |
| Globus Medical, INC. | $14.71 | 2025 | Senza |
| Corium, LLC | $14.34 | 2023 | Adlarity |
| Intra-Sana Laboratories | $14.27 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Carrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.